AQA 39*, a new bradycardic agent which blocks myocardial calcium (Ca) channels in a frequency- and voltage-dependent manner.
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D004558:Electric Stimulation; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D066298:In Vitro Techniques; D007473:Ion Channels / Q000378:metabolism*; D054833:Isoindoles; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism*; D010797:Phthalimides / Q000494:pharmacology*; D011817:Rabbits
D007473:Ion Channels; D054833:Isoindoles; D010797:Phthalimides; C030532:falipamil